Tag: risk

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

New York, NY, June 05, 2026 (GLOBE NEWSWIRE) -- InterPrivate Investment Partners V, Inc. (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced the closing of its initial public offering of 20,125,000 units, including 2,625,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full, at a price of $10.00 per unit on June 5, 2026. Total gross proceeds from the offering were $201.25 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

TORTOLA, British Virgin Islands, June 05, 2026 (GLOBE NEWSWIRE) -- Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim (unaudited) financial statements and management’s discussion and analysis for the three month period ended March 31, 2026 (“Q1 2026”) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated.